TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management.

Am J Hematol · 2025 · PMC12067166 · PMID 40066944

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

[ 137 ], of the 16 TP53 mut MN who underwent alloHCT, 7 achieved a clearance of TP53 mut (by NGS) pre‐alloHCT and had a numerical trend towards improved survival (25.2 vs. 11.7 months).

also in 536 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.